BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 27595376)

  • 1. Assessing Metastatic Disease in Advanced Prostate Cancer: It's Time to Change Imaging.
    Barentsz JO; Mulders P; Gerritsen W; Fütterer JJ
    Eur Urol; 2017 Jan; 71(1):93-95. PubMed ID: 27595376
    [No Abstract]   [Full Text] [Related]  

  • 2. Is surgery good for advanced localised prostate cancer? It's time to find out!
    Lange PH
    Eur Urol; 2007 Apr; 51(4):873-5. PubMed ID: 17070648
    [No Abstract]   [Full Text] [Related]  

  • 3. Spirituality in men with advanced prostate cancer: "it's a holistic thing . . . it's a package".
    Lepherd L
    J Holist Nurs; 2014 Jun; 32(2):89-101; quiz 102-3. PubMed ID: 24080341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. It's time to change the treatment paradigm for prostate cancer!
    Studer UE; Albertsen PC
    Eur Urol; 2013 Jan; 63(1):97-9; discussion 99-100. PubMed ID: 22959353
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 6. Fibrinolysis in metastatic cancer of the prostate.
    TAGNON HJ; WHITMORE WF; SHULMAN NR
    Cancer; 1952 Jan; 5(1):9-12. PubMed ID: 14886894
    [No Abstract]   [Full Text] [Related]  

  • 7. [Advances in the biochemical diagnosis of metastatic cancer of the prostate].
    RAABE S
    Zentralbl Chir; 1952; 77(43a):1888-96. PubMed ID: 13039475
    [No Abstract]   [Full Text] [Related]  

  • 8. The significance of fibrinolysis occurring in patients with metastatic cancer of the prostate.
    TAGNON HJ; WHITMORE WF; SCHULMAN P; KRAVITZ SC
    Cancer; 1953 Jan; 6(1):63-7. PubMed ID: 13009653
    [No Abstract]   [Full Text] [Related]  

  • 9. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
    Thompson IM; Ankerst DP; Etzioni R; Wang T
    J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
    [No Abstract]   [Full Text] [Related]  

  • 10. On low acid phosphatase values of patients with known metastatic cancer of the prostate.
    LONDON M; McHUGH R; HUDSON PB
    Cancer Res; 1954 Nov; 14(10):718-24. PubMed ID: 13209548
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic impact of synchronous second primary malignancies on the overall survival of patients with metastatic prostate cancer.
    Koo KC; Yoo H; Kim KH; Park SU; Han KS; Rha KH; Hong SJ; Yang SC; Chung BH
    J Urol; 2015 Apr; 193(4):1239-44. PubMed ID: 25444987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of cyren therapy on metastasis of prostate cancer].
    DAMMERMANN HJ
    Z Urol; 1951; 44(4):233-5. PubMed ID: 14837213
    [No Abstract]   [Full Text] [Related]  

  • 13. Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea.
    Beer TM
    Health News; 2003 Aug; 9(8):1-2. PubMed ID: 12971313
    [No Abstract]   [Full Text] [Related]  

  • 14. [Metastases in cancer of the prostate].
    de FREITAS FILHO F; BRANDAO FA; PINOTTI DO
    Rev Bras Cir; 1962 Jul; 44():64-9. PubMed ID: 13894996
    [No Abstract]   [Full Text] [Related]  

  • 15. [Diagnosis and treatment of prostate cancer--it's diversity and future prospects].
    Ogawa O
    Hinyokika Kiyo; 2001 Feb; 47(2):131-8. PubMed ID: 11280887
    [No Abstract]   [Full Text] [Related]  

  • 16. [On a metastasis of a prostatic cancer simulating an osteoma].
    HORVATH F; GALLE T; TOTH J
    Fortschr Geb Rontgenstr Nuklearmed; 1960 May; 92():587-8. PubMed ID: 14403249
    [No Abstract]   [Full Text] [Related]  

  • 17. Is metastatic prostate cancer changing, and how will we know it? It's time for standard nomenclature for nonosseous metastases in clinical trials of patients with metastatic castration resistant prostate cancer.
    Tsao CK; Galsky MD; Oh WK
    Eur Urol; 2014 Aug; 66(2):184-5. PubMed ID: 24433812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgical management of a locally advanced symptomatic recurrence of penile sarcoma secondary to prostate brachytherapy.
    Hakky TS; Espiritu P; Rodriguez AR; Gould N; Spiess PE
    Int Braz J Urol; 2013; 39(2):293-4. PubMed ID: 23683678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer screening: why it's not for every man.
    Lakhan SE
    Medscape J Med; 2008; 10(8):182; author reply 182. PubMed ID: 18924634
    [No Abstract]   [Full Text] [Related]  

  • 20. Radiation therapy for node-positive prostate cancer: it's time for a randomized trial.
    Nguyen PL
    Oncology (Williston Park); 2015 Feb; 29(2):116-7. PubMed ID: 25683832
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.